Advertisement
 
YOU ARE HERE: LAT HomeCollectionsIcn Biomedicals Inc
IN THE NEWS

Icn Biomedicals Inc

FEATURED ARTICLES
ARTICLES BY DATE
BUSINESS
November 12, 2003 | Ronald D. White, Times Staff Writer
ICN Pharmaceuticals' mission was to come up with a name that had panache -- but not Panic. Three months and $1 million later, executives have settled on Valeant Pharmaceuticals International. The appellation, which will be unveiled today, will help distance the Costa Mesa company from its checkered past and flamboyant founder, Milan Panic, while conveying a renewed sense of "values" and "vitality," said Timothy Tyson, president and chief operating officer.
Advertisement
BUSINESS
May 15, 1992
ICN Biomedicals Inc., the Costa Mesa supplier of biotechnology research products and medical diagnostics, reported a first-quarter net loss of $781,000, or 5 cents a share, contrasted with a profit of $553,000, or 5 cents a share, a year earlier. The company said it expects its previously announced restructuring to return it to profitability in the latter part of 1992. Sales for the latest quarter dropped 28% to $21.2 million from $29.5 million.
BUSINESS
November 12, 1994 | From Times Staff and Wire Reports
ICN Merger Complete: Costa Mesa-based ICN Pharmaceuticals Inc. said Friday that it has completed its merger with three affiliated corporations: SPI Pharmaceuticals, ICN Biomedicals and Viratek. Each share of pre-merger ICN Pharmaceuticals stock will be converted to 0.512 share of new ICN common stock. Each share of SPI stock will be converted to a full share of new ICN common stock. Viratek shares will be converted at the rate of one for each 0.
BUSINESS
March 28, 1992 | ANNE MICHAUD, SPECIAL TO THE TIMES
ICN Biomedicals Inc., which employs 276 people in Costa Mesa and Irvine, announced Friday that it intends to broadly restructure its business. The company said layoffs are likely, but it has not decided yet which jobs to eliminate. It said the move is an attempt to refocus its business strategies and become more competitive.
BUSINESS
August 6, 1987
ICN Biomedicals Inc., a subsidiary of ICN Pharmaceuticals Inc. in Costa Mesa, said Wednesday that it has agreed to purchase Radioassay Systems Laboratories and Immuchem Corp. of Carson. Terms of the deal, which is scheduled to close this month, were not disclosed. RSL and its sales arm, Immuchem, reported total sales of $6 million in 1986.
BUSINESS
November 2, 1994 | HOPE HAMASHIGE, SPECIAL TO THE TIMES
Creating a corporation with $500 million in annual sales, shareholders of ICN Pharmaceuticals and three affiliates on Tuesday approved a merger of the four into a single company. ICN said it expects federal regulators to give their approval next week for its combination with Viratek Inc., SPI Pharmaceuticals and ICN Biomedicals. The new company will operate under the name ICN Pharmaceuticals, and its stock will be traded on the New York Stock Exchange.
BUSINESS
October 31, 1994 | From Times Staff and Wire Reports
ICN Seeks Merger OK: ICN Pharmaceuticals Inc. will urge shareholders at its annual meeting Tuesday to approve an intra-company merger that would consolidate three partially owned subsidiaries. To streamline operations and create a company with $500 million in sales, the Costa Mesa company wants shareholders of SPI Pharmaceuticals Inc., Viratek Inc. and ICN Biomedicals Inc. to accept one share of ICN stock for each share of their stock.
BUSINESS
August 3, 1994 | DEBORA VRANA, TIMES STAFF WRITER
ICN Pharmaceuticals in Costa Mesa said Thursday that it plans to streamline its operations by merging with its three affiliates, creating a new company with $500 million in annual sales. If shareholders and federal regulators approve the proposal, the new company, which will keep the name ICN Pharmaceuticals, would begin trading on the New York Stock Exchange this fall.
BUSINESS
July 27, 1993 | James M. Gomez / Times staff writer
Four New Divisions: ICN Biomedicals Inc., a subsidiary of Costa Mesa-based drug conglomerate ICN Pharmaceuticals Inc., has just completed a restructuring. The company, which manufactures and sells chemicals and instruments for medical research and development, has divided itself into four divisions for greater efficiency, said ICN spokesman Paul Knopick.
BUSINESS
July 18, 1991
ICN Biomedicals Inc. of Costa Mesa posted second-quarter earnings of $1.2 million, down 57% from earnings of $2.8 million in the year-earlier quarter. Revenue for the quarter ended May 31 declined 25% to $26.6 million from $35.3 million a year earlier. For the six-month period, earnings dropped 51% to $2.3 million from $4.7 million a year ago. Revenue declined 18% to $56.3 million from $68.3 million.
BUSINESS
February 22, 1994 | James M. Gomez, Times staff writer
Bare Bones: Are you suffering from an overpowering desire to know just how human bones are formed? If so, then ICN Biomedicals, a subsidiary of ICN Pharmaceuticals Inc., has just the chemical for you. ICN Biomedicals said it is now selling tubulin, a protein that is a necessary component in cell structure and the formation of new cells. So far so good.
Los Angeles Times Articles
|